Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Current Deferred Revenue (2020 - 2024)

Allogene Therapeutics (ALLO) has disclosed Current Deferred Revenue for 5 consecutive years, with $86000.0 as the latest value for Q1 2024.

  • Quarterly Current Deferred Revenue changed 0.0% to $86000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $86000.0 through Mar 2024, changed 0.0% year-over-year, with the annual reading at $86000.0 for FY2023, 9.47% down from the prior year.
  • Current Deferred Revenue hit $86000.0 in Q1 2024 for Allogene Therapeutics, roughly flat from $86000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $39.0 million in Q4 2020 to a low of $86000.0 in Q1 2023.
  • Historically, Current Deferred Revenue has averaged $2.9 million across 5 years, with a median of $101500.0 in 2022.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 99.6% in 2021 and later changed 0.0% in 2024.
  • Year by year, Current Deferred Revenue stood at $39.0 million in 2020, then crashed by 99.6% to $156000.0 in 2021, then tumbled by 39.1% to $95000.0 in 2022, then fell by 9.47% to $86000.0 in 2023, then changed by 0.0% to $86000.0 in 2024.
  • Business Quant data shows Current Deferred Revenue for ALLO at $86000.0 in Q1 2024, $86000.0 in Q4 2023, and $86000.0 in Q3 2023.